Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin

We assessed peripheral and liver CXCL10 levels in 15 patients treated with telaprevir/pegylated interferon/ribavirin. Induction of peripheral CXCL10 messenger RNA (mRNA) peaked (mean fold-induction [±SD], 3.1±1.9) between treatment hour 6 and day 2, while induction of intrahepatic CXCL10 mRNA peaked...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2015-06, Vol.211 (11), p.1795-1799
Main Authors: Zeremski, Marija, Dimova, Rositsa B., Benjamin, Samantha, Penney, Marina S., Botfield, Martyn C., Talal, Andrew H.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Chemokine CXCL10 - analysis
Chemokine CXCL10 - blood
Chemokine CXCL10 - genetics
Chemokine CXCL10 - metabolism
Female
Hepacivirus - drug effects
Hepatitis C virus
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - epidemiology
Hepatitis C, Chronic - immunology
Humans
Interferon-alpha - pharmacology
Interferon-alpha - therapeutic use
Liver - chemistry
Liver - immunology
Liver - metabolism
Major and Brief Reports
Male
Middle Aged
Oligopeptides - pharmacology
Oligopeptides - therapeutic use
Polyethylene Glycols - pharmacology
Polyethylene Glycols - therapeutic use
Recombinant Proteins - pharmacology
Recombinant Proteins - therapeutic use
Ribavirin - pharmacology
Ribavirin - therapeutic use
Viral Load - drug effects
VIRUSES
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We assessed peripheral and liver CXCL10 levels in 15 patients treated with telaprevir/pegylated interferon/ribavirin. Induction of peripheral CXCL10 messenger RNA (mRNA) peaked (mean fold-induction [±SD], 3.1±1.9) between treatment hour 6 and day 2, while induction of intrahepatic CXCL10 mRNA peaked (mean fold-induction [±SD], 1.3 ± 0.54) at hour 10 or day 4. Peripheral CXCL10 levels were higher at treatment hour 10 (P = .032) and day 2 (P = .009) in patients with undetectable virus 2 weeks after treatment initiation. Treatment hour 10 (P = .023) and peak (P = .034) intrahepatic CXCL10 levels were also higher in these patients. CXCL10 did not distinguish treatment responders from nonresponders. In conclusion, CXCL10 identified very rapid virological response in patients treated with a direct-acting antiviral.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiu807